Paper Details

  1. Home
  2. Paper Details

Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.

Author: FeigeUrsula, HamedEbrahem, HanftKlara-Maria, HettmerSimone, KaiserMax, KrengelSven, MeissFrank, NiemeyerCharlotte, PietschTorsten, SchneiderMichaela, WürtembergerJulia

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reports on a child with a rare cancer called congenital melanocytic nevus (CMN) syndrome. The child was successfully treated with a combination of azacitidine and trametinib. This combination therapy was more effective than trametinib alone and might be a promising treatment for other RAS-driven cancers.
Paper Details　
Original Abstract of the Article :
Congenital melanocytic nevus (CMN) syndrome represents a mosaic RASopathy, typically caused by postzygotic NRAS codon 61 mutations, which originate in ectodermal precursor cells and result in melanocyte deposits in the skin and central nervous system (CNS). Affected patients are prone to develop uni...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/pbc.29468

データ提供：米国国立医学図書館（NLM）

Combinatorial Therapy for NRAS-Mutated Melanoma

The fight against cancer often feels like a journey through a vast and unforgiving desert. This study explores the potential of combining azacitidine, a DNA methyltransferase inhibitor, with trametinib, a MEK inhibitor, as a therapeutic approach for NRAS-mutated melanoma. The researchers investigated the efficacy of this combination therapy in a case study of a young patient with congenital melanocytic nevus (CMN) syndrome and CNS melanoma. The findings demonstrate exceptional clinical and radiological response to the combination therapy, highlighting its potential for treating this aggressive form of cancer. The study also provides in vitro evidence suggesting that azacitidine can enhance the effectiveness of trametinib and potentially overcome resistance to MEK inhibitors in NRAS-mutated melanoma cells. This research offers a promising path forward in the development of more effective treatments for this challenging cancer.

Combating Melanoma with a Novel Combination Therapy

This research sheds light on the potential of combining azacitidine and trametinib as a novel therapeutic strategy for NRAS-mutated melanoma. The study's findings suggest that this combination therapy could offer a new oasis in the desert of melanoma treatment options, providing hope for patients facing this aggressive form of cancer.

Navigating the Challenges of NRAS-Mutated Melanoma

The development of more effective treatments for NRAS-mutated melanoma is a priority for researchers. This study highlights the potential of combination therapy involving azacitidine and trametinib as a promising approach to combat this aggressive form of cancer. The findings offer hope for individuals facing this challenging disease, providing a potential path toward improved treatment outcomes.

Dr.Camel's Conclusion

This study presents a novel and promising therapeutic approach for NRAS-mutated melanoma, combining azacitidine and trametinib. The findings demonstrate exceptional clinical response in a case study and suggest that this combination therapy could overcome resistance to MEK inhibitors. This research offers a potential oasis in the desert of melanoma treatment options, paving the way for more effective and targeted therapies for this aggressive form of cancer.

Date :
  1. Date Completed 2022-05-04
  2. Date Revised 2022-05-04
Further Info :

Pubmed ID

34866327

DOI: Digital Object Identifier

10.1002/pbc.29468

Related Literature

Article Analysis
・Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.